Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

820

Participants

Timeline

Start Date

December 1, 2002

Primary Completion Date

December 1, 2004

Study Completion Date

December 1, 2004

Conditions

NauseaVomitingBreast Neoplasms

Interventions

DRUG

MK0869, aprepitant / Duration of Treatment: 3 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092196 - Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) | Biotech Hunter | Biotech Hunter